Loading stock data…
$1.42-0.15 (-9.55%)
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
ProKidney Corp. in the Healthcare sector is trading at $1.42 with a market capitalization of $734M. Wall Street consensus targets $6.25 (6 analysts), implying a +340.1% move over the next 12 months. The stock is currently near its 52-week low of $1.30, remaining 24.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $150,000↓ | $226,000↑ | $225,000↑ | $217,000↓ | $221,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.37M↓ | -$44.93M↑ | -$45.37M↓ | -$38.54M↑ | -$39.71M |
| Net Income | -$28.42M↓ | -$20.04M↓ | -$19.23M↓ | -$16.47M↑ | -$16.55M |
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal c...